These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8356623)

  • 1. Improving renal transplant outcomes in African Americans with OKT3 induction therapy.
    Light JA; Kelly JL; Aquino A; Neu L; DeNavas L; Williams K
    Transplant Proc; 1993 Aug; 25(4):2436-8. PubMed ID: 8356623
    [No Abstract]   [Full Text] [Related]  

  • 2. OKT3 induction therapy and cadaveric renal transplantation in black patients.
    Reinitz ER; Kaplan MP; Sillix DH; Lysz K
    Transplant Proc; 1997 Dec; 29(8):3703-5. PubMed ID: 9414892
    [No Abstract]   [Full Text] [Related]  

  • 3. The fate of renal allografts treated with OKT3 for steroid-resistant rejection.
    Veronese FV; Gonçalves LF; Vilarinho LL; Macedo VS; Manfro RC
    Transplant Proc; 1999 Nov; 31(7):3016-8. PubMed ID: 10578371
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term results of OKT3-treated renal transplant recipients.
    Tanabe K; Takahashi K; Sonda K; Tokumoto T; Koga S; Nakazawa H; Goya N; Yagisawa T; Fuchinoue S; Kawai T; Toma H; Ota K
    Transplant Proc; 1996 Jun; 28(3):1350-1. PubMed ID: 8658689
    [No Abstract]   [Full Text] [Related]  

  • 5. Simulect, calcineurin inhibitor, mycophenolate mofetil, and prednisone is more effective than OKT3, calcineurin inhibitor, hycophendate mofetil, and prednisone in African American kidney recipients in reducing acute rejections and prolonging graft survival.
    Kumar AM; Fa K; Vankawala R; Vora M; Kode RK; Pankewycz OG; Lattavi MR; Fyfe B; Damask AM; Ferry E; Stabler S; Tomeny MB; Phillips K; Lingaraju R; Kumar MS
    Transplant Proc; 2001; 33(7-8):3195-6. PubMed ID: 11750370
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of OKT3 treatment for steroid resistant rejection of renal allografts: the long-term outcome at a single center.
    Inui M; Tanabe K; Ishikawa N; Tokumoto T; Harano M; Otsubo S; Suzuki K; Goya N; Yagisawa T; Nakazawa H; Fuchinoue S; Toma H
    Transplant Proc; 1999 Nov; 31(7):2870-1. PubMed ID: 10578320
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
    Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
    Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
    [No Abstract]   [Full Text] [Related]  

  • 8. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
    Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ
    Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461
    [No Abstract]   [Full Text] [Related]  

  • 9. Sirolimus in late acute OKT3-resistant and/or steroid-resistant rejection after simultaneous pancreas and kidney transplantation.
    Kahl A; Oppert M; Müller A; Settmacher U; Lepenies J; Klupp J; Kampf D; Neuhaus P; Frei U
    Transplant Proc; 2002 Sep; 34(6):2253-5. PubMed ID: 12270387
    [No Abstract]   [Full Text] [Related]  

  • 10. Donor bone marrow infusion in simultaneous pancreas/kidney transplantation with OKT3 induction: evidence for augmentation of chimerism.
    Burke GW; Ricordi C; Karatzas T; Carreno M; Markou M; Cirocco R; Ciancio G; Qian T; Selvaggi G; Alejandro R; Skyler JS; Roth D; Tzakis A; Miller J
    Transplant Proc; 1997; 29(1-2):1207-8. PubMed ID: 9123275
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical and renal histologic predictors of long-term outcome after OKT3 therapy for steroid-resistant rejection.
    Wiener Y; Nakhleh RE; Kupin WL; Lee M; Escobar FS; Venkat KK; Mozes MF
    Transplant Proc; 1995 Feb; 27(1):1014-5. PubMed ID: 7878781
    [No Abstract]   [Full Text] [Related]  

  • 12. Individualization of immunosuppressive therapy: I. Sirolimus improves outcomes in African-American renal transplant recipients.
    Podder H; Kahan BD
    Transplant Proc; 2005 Nov; 37(9):3723-6. PubMed ID: 16386518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALG versus OKT3 for treatment of steroid-resistant rejection in renal transplantation: ten-year follow-up results of a randomized trial.
    Stippel DL; Arns W; Pollok M; Beckurts KT; Hesse UJ; Hölscher AH
    Transplant Proc; 2002 Sep; 34(6):2201-2. PubMed ID: 12270362
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of reduced dose of OKT3 (2.5 mg) after renal transplantation.
    Machado PG; Tedesco HS; Silva RG; Pacheco-Silva A; Medina JO
    Transplant Proc; 2002 Feb; 34(1):104. PubMed ID: 11959207
    [No Abstract]   [Full Text] [Related]  

  • 15. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
    Schulz T; Papapostolou G; Schenker P; Kapischke M
    Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OKT3 first-line treatment of acute rejection episodes following combined pancreas and kidney transplantation.
    Cantarovich D; Hourmant M; Dantal J; Giral M; Paineau J; Karam G; Soulillou JP
    Transplant Proc; 1994 Apr; 26(2):549. PubMed ID: 8171548
    [No Abstract]   [Full Text] [Related]  

  • 17. ATG versus OKT3 in the treatment of steroid-resistant rejection following living-related donor renal transplantation.
    Uslu A; Tokat Y; Ok E; Unsal A; Ilkgul O; Kaplan H
    Transplant Proc; 1997 Nov; 29(7):2805-6. PubMed ID: 9365571
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients.
    Piatosa B; Grenda R; Prokurat S
    Transplant Proc; 1993 Aug; 25(4):2574. PubMed ID: 8356675
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined pancreas-kidney transplantation versus kidney transplantation alone: analysis of benefit and risk.
    Stratta RJ; Taylor RJ; Ozaki CF; Bynon JS; Langnas AN; Shaw BW
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1298-301. PubMed ID: 8442119
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of tacrolimus as the primary immunosuppression after renal transplant in Native Americans and Hispanics.
    Eghtesad B; Malhotra D; Hecker WP; Haq M; Gibel LJ; Wheeler D; Smith AY; Harford AM
    Transplant Proc; 1998 Jun; 30(4):1232-3. PubMed ID: 9636500
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.